Showing results (1-10 of 1,332) with videos related to
Sort By:
Pageof 134
JAMA Cardiology|March 29, 2020
Potential Effects of Coronaviruses on the Cardiovascular System: A ReviewMohammad Madjid, Payam Safavi-Naeini, Scott D Solomon, et al.Cardiology Clinics|October 22, 2008
Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular riskOrly Vardeny, Scott D SolomonJACC. Heart Failure|October 13, 2014
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failureOrly Vardeny, Ryan Miller, Scott D SolomonExpert Review of Cardiovascular Therapy|May 15, 2015
Does influenza vaccination influence cardiovascular complications?Jacob A Udell, Michael E Farkouh, Scott D Solomon, et al.European Heart Journal|March 22, 2021
Influenza vaccination: a 'shot' at INVESTing in cardiovascular healthAnkeet S Bhatt, Orly Vardeny, Jacob A Udell, et al.The American Journal of Medicine|September 9, 2019
The Sweet Spot: Heart Failure Prevention with SGLT2 InhibitorsOrly VardenyJournal of the American College of Cardiology|October 23, 2012
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)Orly Vardeny, Dong Hong Wu, Akshay Desai, et al.Clinical Pharmacology and Therapeutics|October 19, 2023
High-Dose vs. Standard-Dose Influenza Vaccine and Cardiopulmonary Hospitalization or Mortality: Emulating the INVESTED Trial Using Insurance Claims DataMehdi NajafZadeh, HoJin Shin, Sebastian Schneeweiss, et al.Circulation. Heart Failure|May 10, 2014
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonistOrly Vardeny, Brian Claggett, Inder Anand, et al.Pharmacotherapy|April 6, 2023
Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fractionOrly Vardeny, Hailee HoulePageof 134